On Tuesday, Terns Pharmaceuticals Inc (NASDAQ: TERN) opened higher 8.37% from the last session, before settling in for the closing price of $6.69. Price fluctuations for TERN have ranged from $1.87 to $11.40 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 16.38%. Company’s average yearly earnings per share was noted 0.97% at the time writing. With a float of $69.58 million, this company’s outstanding shares have now reached $87.47 million.
Terns Pharmaceuticals Inc (TERN) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Terns Pharmaceuticals Inc is 20.49%, while institutional ownership is 77.72%. The most recent insider transaction that took place on Jul 01 ’25, was worth 3,640. In this transaction Chief Medical Officer of this company sold 853 shares at a rate of $4.27, taking the stock ownership to the 52,464 shares. Before that another transaction happened on Jun 27 ’25, when Company’s Chief Financial Officer bought 10,000 for $3.93, making the entire transaction worth $39,283. This insider now owns 25,000 shares in total.
Terns Pharmaceuticals Inc (TERN) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.28 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.32) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.29 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 0.97% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -7.43% during the next five years compared to 16.38% growth over the previous five years of trading.
Terns Pharmaceuticals Inc (NASDAQ: TERN) Trading Performance Indicators
Check out the current performance indicators for Terns Pharmaceuticals Inc (TERN). In the past quarter, the stock posted a quick ratio of 24.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.05, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.23 in one year’s time.
Technical Analysis of Terns Pharmaceuticals Inc (TERN)
Compared to the last year’s volume of 1.17 million, its volume of 1.02 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 74.52%.
During the past 100 days, Terns Pharmaceuticals Inc’s (TERN) raw stochastic average was set at 99.81%, which indicates a significant increase from 99.48% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.45 in the past 14 days, which was higher than the 0.31 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.39, while its 200-day Moving Average is $4.55. Nevertheless, the first resistance level for the watch stands at $7.44 in the near term. At $7.63, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.00. If the price goes on to break the first support level at $6.88, it is likely to go to the next support level at $6.51. Should the price break the second support level, the third support level stands at $6.32.
Terns Pharmaceuticals Inc (NASDAQ: TERN) Key Stats
There are currently 87,511K shares outstanding in the company with a market cap of 634.46 million. Presently, the company’s annual sales total 0 K according to its annual income of -88,850 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -24,090 K.
